Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Barrios

Showing results (91-100 of 183) with videos related to

Pageof 19
Sort By:
British Journal of Cancer|January 18, 2014
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaT E Hutson, R M Bukowski, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2026
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>†</sup>E de Azambuja, C H Barrios, R Bartsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2022
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 TrialJens Huober, Carlos H Barrios, Naoki Niikura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Research needs in breast cancerF Cardoso, N Harbeck, C H Barrios, et al.
The Lancet. Oncology|December 2, 2019
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trialPeter Schmid, Hope S Rugo, Sylvia Adams, et al.
ESMO Open|January 28, 2026
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancerK L Jhaveri, N M Iyengar, N C Turner, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2013
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety updateCora N Sternberg, Robert E Hawkins, John Wagstaff, et al.
Plos One|August 28, 2018
Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational studyDae Ho Lee, Ming-Sound Tsao, Karl-Otto Kambartel, et al.
Journal of the National Cancer Institute|February 1, 2021
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyLeisha A Emens, Luciana Molinero, Sherene Loi, et al.
Journal of Global Oncology|November 27, 2019
Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: A Multinational StudyMax S Mano, Rafaela Gomes, Gustavo Werutsky, et al.
Pageof 19

Showing results (91-100 of 183) with videos related to

Sort By:
Pageof 19
British Journal of Cancer|January 18, 2014
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinomaT E Hutson, R M Bukowski, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2026
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up<sup>†</sup>E de Azambuja, C H Barrios, R Bartsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2022
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 TrialJens Huober, Carlos H Barrios, Naoki Niikura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Research needs in breast cancerF Cardoso, N Harbeck, C H Barrios, et al.
The Lancet. Oncology|December 2, 2019
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trialPeter Schmid, Hope S Rugo, Sylvia Adams, et al.
ESMO Open|January 28, 2026
Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancerK L Jhaveri, N M Iyengar, N C Turner, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2013
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety updateCora N Sternberg, Robert E Hawkins, John Wagstaff, et al.
Plos One|August 28, 2018
Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational studyDae Ho Lee, Ming-Sound Tsao, Karl-Otto Kambartel, et al.
Journal of the National Cancer Institute|February 1, 2021
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyLeisha A Emens, Luciana Molinero, Sherene Loi, et al.
Journal of Global Oncology|November 27, 2019
Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: A Multinational StudyMax S Mano, Rafaela Gomes, Gustavo Werutsky, et al.
Pageof 19